NEW
YORK, May 8, 2024 /PRNewswire/ -- Lindus Health,
an anti-CRO running radically faster, more reliable clinical trials
for life science pioneers, is announcing the appointment of Dr.
Tim Garnett, pharma industry leader
and former Chief Medical Officer at Eli Lilly, to their advisory
board. This significant move follows closely on the heels of the
company's previous addition of advisor Dr. Robert Langer, Institute Professor of
Massachusetts Institute of Technology
(MIT), and co-founder of Moderna,
Inc.
Dr. Garnett is a board member of leading biotechs like
Maplight Therapeutics and Ophirex, Inc., as well as an advisor to
Ukko and Biolojic Design. He holds more than 30 years of experience
pioneering clinical development, medical affairs, and regulatory
operations worldwide, predominantly during his tenure at Eli Lilly,
with a focus on women's health, metabolic diseases, and CNS
conditions. Dr. Garnett has also successfully transformed drug
safety and regulatory organizations and enhanced drug development
and approval processes on a global scale.
"We're incredibly excited to welcome Dr. Garnett to our advisory
board. His unparalleled medical experience and deep therapeutic
area expertise in neuroscience, endocrinology, and women's health
will serve us and our clinical trial sponsors," said Meri Beckwith, Lindus Health Co-Founder. "The
opportunity to learn from and collaborate with him is incredibly
humbling, and we eagerly anticipate the transformative impact this
partnership will bring."
"Lindus Health puts great emphasis on aligning incentives with
sponsors, and their risk-sharing, milestone-based payment model is
much needed in the CRO industry," states Dr. Garnett. "Their
patient and technology-centric approach to clinical trials will
greatly benefit biotech and pharmaceutical companies, enabling
faster, cost-effective studies. I'm eager to support Lindus
Health's growth in CNS, women's health, and metabolic disease
therapeutics - areas where my contributions have played a pivotal
role in advancing treatments."
For more information, please visit www.lindushealth.com.
About Lindus Health
Lindus Health is an anti-CRO running radically faster and more
reliable trials for life science pioneers – bringing
ground-breaking treatments to patients more quickly. Lindus
Health does this thanks to a commercial model that aligns
incentives (fixed-priced quotes per study, with milestone-based
payments), marrying a world-class clinical operations team with its
unique software platform, and access to 30 million Electronic
Health Records. Clinical trials are the biggest bottleneck to
advances in healthcare and by removing this constraint they aim to
improve health for everyone. They handle the end-to-end execution
of clinical studies, including design, patient recruitment,
clinical data capture, monitoring and project management.
To date, Lindus Health has delivered more than 90 trials
across the US, UK and Europe to
tackle a range of conditions including diabetes, asthma, acne,
social anxiety, major depressive disorder, hypertension, chronic
fatigue syndrome and insomnia.
The company was named after James Lind, who pioneered the
first clinical trial and treatment for scurvy, and co-founded by
Michael Young, a former Special
Adviser to the UK Prime Minister on Life Sciences, and Meri Beckwith, a former life sciences
investor.
Lindus Health has raised over $24M
from investors including Peter
Thiel, CREANDUM, Firstminute Capital, Presight Capital,
Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.
Media Contact
Jodi
Perkins
Amendola for Lindus Health
jperkins@acmarketingpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/dr-tim-garnett-former-chief-medical-officer-of-eli-lilly-joins-lindus-healths-advisory-board-302127131.html
SOURCE Lindus Health